Fulcrum Therapeutics Inc. (NASDAQ: FULC) reported Q1 EPS of ($0.41), $0.05 better than the analyst estimate of ($0.46). Revenue for the quarter came in at $300 thousand versus the consensus estimate of $1.14 million.

For earnings history and earnings-related data on Fulcrum Therapeutics Inc. (FULC) click here.